TY - JOUR
T1 - Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study
AU - Schutters, Sara I. J.
AU - van Megen, Harold J. G. M.
AU - van Veen, Jantien Frederieke
AU - Denys, Damiaan A. J. P.
AU - Westenberg, Herman G. M.
PY - 2010
Y1 - 2010
N2 - This study is aimed at investigating the efficacy and tolerability of mirtazapine in a generalized social anxiety disorder. Sixty patients with generalized social anxiety disorder were randomly allocated to receive mirtazapine (30-45 mg/day) (n = 30) or placebo (n = 30) for 12 weeks in a double-blind study design. Primary efficacy was assessed by the Liebowitz Social Anxiety Scale (LSAS) and response to treatment was defined as a reduction of 40% on the LSAS and an improvement on the Clinical Global Impression scale of 'much or very much improved'. An intent-to-treat analysis showed no difference between mirtazapine and placebo on the absolute LSAS scores with a mean decrease of 13.5 +/- 16.9 and 11.2 +/- 17.8 respectively, and on the number of responders, 13 and 13%, respectively. In conclusion, mirtazapine (30-45 mg/day) failed to be effective in the generalized social anxiety disorder. Int Clin Psychopharmacol 25: 302-304 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
AB - This study is aimed at investigating the efficacy and tolerability of mirtazapine in a generalized social anxiety disorder. Sixty patients with generalized social anxiety disorder were randomly allocated to receive mirtazapine (30-45 mg/day) (n = 30) or placebo (n = 30) for 12 weeks in a double-blind study design. Primary efficacy was assessed by the Liebowitz Social Anxiety Scale (LSAS) and response to treatment was defined as a reduction of 40% on the LSAS and an improvement on the Clinical Global Impression scale of 'much or very much improved'. An intent-to-treat analysis showed no difference between mirtazapine and placebo on the absolute LSAS scores with a mean decrease of 13.5 +/- 16.9 and 11.2 +/- 17.8 respectively, and on the number of responders, 13 and 13%, respectively. In conclusion, mirtazapine (30-45 mg/day) failed to be effective in the generalized social anxiety disorder. Int Clin Psychopharmacol 25: 302-304 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
U2 - https://doi.org/10.1097/YIC.0b013e32833a4d71
DO - https://doi.org/10.1097/YIC.0b013e32833a4d71
M3 - Article
C2 - 20715300
SN - 0268-1315
VL - 25
SP - 302
EP - 304
JO - International Clinical Psychopharmacology
JF - International Clinical Psychopharmacology
IS - 5
ER -